by admin | Jan 26, 2023 | News & Opinions
By Andrea Park, Conor Hale – Fierce Biotech SAN FRANCISCO—After years of stops, starts and stops again, the J.P. Morgan Healthcare Conference has returned to the city by the bay in full form. Below we’ve compiled the biggest medtech news so far,...
by admin | Jan 25, 2023 | News & Opinions
Manipulating Cell Signaling Can Possibly Ensure the Body Has a Healthy Amount of Cells By Stephanie Cajigal – Cedars Sinai A new study led by Cedars-Sinai and the University of California, San Francisco (UCSF), has determined that altering a cellular process can...
by admin | Jan 24, 2023 | News & Opinions
By Allison Gatlin – Investors.com If there’s one overarching theme that investors in biotech stocks should pay attention to in 2023, it’s “genetic medicine, genetic medicine, genetic medicine,” says Christopher Anzalone. Anzalone is...
by admin | Jan 22, 2023 | News & Opinions
Michael Druckman, Meredith Manning, and Ashley Grey – Hogan Lovells Last year, a federal court in California ruled against the U.S. Food and Drug Administration (FDA) in a matter where the government alleged that a stem cell clinic’s products should be...
by admin | Jan 20, 2023 | News & Opinions
by William A. Haseltine – Forbes Here we describe early clinical trial results on combination CRISPR and CAR T therapy, a sequel to an earlier, introductory piece. Other alternative CAR T designs include mRNA vectors to create temporary CAR T cells and the use...
